非ステロイド性抗炎症薬の世界市場レポート 2025年

非ステロイド性抗炎症薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.8％で287億9,000万米ドルに成長します。予測期間の成長は、新たな疼痛管理療法、規制変更、遠隔医療利用、世界のウェルネス動向、バイオシミラー競合、患者の嗜好、精密医療アプローチに起因すると考えられます。予測期間の主な動向には、一般用医薬品（OTC）市場の優位性、Cox-2阻害薬への嗜好の高まり、ジェネリック医薬品と市場競争、デジタルヘルス技術の統合、デジタルヘルス技術の統合などがあります。

慢性疼痛の増加は、非ステロイド性抗炎症薬（非ステロイド性抗炎症薬）市場の成長を促進すると予測されます。慢性疼痛は6カ月以上続く不快感と定義され、NSAIDsは一般的に怪我の治療や慢性疼痛の管理に使用されます。例えば、米国を拠点とする非営利団体U.S. Pain Foundationが2022年7月に発表した調査によると、参加者2,378人のうち96%が、3ヵ月以上持続する痛みと定義される慢性疼痛の増加を経験していると報告しています。この中には、2022年3月から4月にかけて調査した介護者の3％とヘルスケア専門家の1％も含まれていました。このように、慢性疼痛の発生率の増加は、非ステロイド性抗炎症薬市場の成長を促進する重要な要因です。

筋骨格系障害（MSD）の有病率の増加は、非ステロイド性抗炎症薬市場の成長を促進します。MSDは、筋骨格系に影響を与え、しばしば疼痛や炎症の管理を必要とする様々な疾患を包含しており、NSAIDsはその主要な治療薬として機能しています。人口動態の高齢化、疾患に対する意識の高まり、整形外科的介入の増加といった要因が、この市場の急拡大に寄与しています。2022年12月にGOV.UKが発表したプロファイルでは、英国の16歳以上の個人におけるMSDの有病率が急上昇していることが強調されており、2021年以降上昇することが指摘されています。この増加は、筋骨格系疾患の負担増とその管理における非ステロイド性抗炎症薬の役割に後押しされた市場の軌道を強調しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の非ステロイド性抗炎症薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の非ステロイド性抗炎症薬市場：成長率分析
• 世界の非ステロイド性抗炎症薬市場の実績：規模と成長, 2019-2024
• 世界の非ステロイド性抗炎症薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界の非ステロイド性抗炎症薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の非ステロイド性抗炎症薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口
• 外用
• その他の投与経路
• 世界の非ステロイド性抗炎症薬市場：疾患適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 関節炎
• 片頭痛
• 眼科疾患
• その他の疾患適応症
• 世界の非ステロイド性抗炎症薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の非ステロイド性抗炎症薬市場：経口のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 錠剤
• カプセル
• 液体または溶液
• 世界の非ステロイド性抗炎症薬市場：外用のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジェル
• クリーム
• パッチ
• 世界の非ステロイド性抗炎症薬市場：その他の投与経路のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 注射剤（静脈内および筋肉内）
• 坐薬

第7章 地域別・国別分析

• 世界の非ステロイド性抗炎症薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の非ステロイド性抗炎症薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 非ステロイド性抗炎症薬市場：競合情勢
• 非ステロイド性抗炎症薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Sun Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Assertio Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Iroko Pharmaceuticals Inc.
• Reckitt Benckiser Group PLC
• Perrigo Company PLC
• Hikma Pharmaceuticals Public Limited Company
• Glenmark Pharmaceuticals Limited
• Septodont
• Aspen Pharmacare Holdings Limited
• Sagent Pharmaceuticals Inc.
• Advanced Pharma Inc.
• Akorn Operating Company LLC
• Alembic Pharmaceuticals Limited
• Torrent Pharmaceuticals Limited
• Lupin Limited
• Cipla Limited
• Zydus Cadila Healthcare Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 非ステロイド性抗炎症薬市場2029：新たな機会を提供する国
• 非ステロイド性抗炎症薬市場2029：新たな機会を提供するセグメント
• 非ステロイド性抗炎症薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Non-steroidal anti-inflammatory drugs (NSAIDs) represent a class of medications designed to alleviate inflammation and reduce fever. They serve as remedies for various ailments including headaches, sprains, painful periods, common colds, flu, arthritis, and other chronic pain conditions. The primary function of NSAIDs is to mitigate inflammation, alleviate pain, and lower elevated body temperatures.

Administration of these drugs primarily occurs through oral ingestion, topical application, and other alternative methods. Topical application is particularly effective in alleviating muscle pains, sprains, and strains, offering relief for painful arthritic conditions. NSAIDs cater to a spectrum of disease indications encompassing arthritis, migraines, ophthalmic disorders, and other related ailments, being accessible through hospital pharmacies, retail outlets, and online pharmacy platforms.

The non-steroidal anti-inflammatory drugs market research report is one of a series of new reports from The Business Research Company that provides non-steroidal anti-inflammatory drugs market statistics, including non-steroidal anti-inflammatory drugs industry global market size, regional shares, competitors with a non-steroidal anti-inflammatory drugs market share, detailed non-steroidal anti-inflammatory drugs market segments, market trends and opportunities, and any further data you may need to thrive in the non-steroidal anti-inflammatory drugs industry. The non-steroidal anti-inflammatory drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-steroidal anti-inflammatory drugs market size has grown strongly in recent years. It will grow from $20.68 billion in 2024 to $22.1 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to chronic inflammatory diseases, postoperative pain management, sports injuries, over-the-counter availability, aging population, consumer awareness.

The non-steroidal anti-inflammatory drugs market size is expected to see strong growth in the next few years. It will grow to $28.79 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to emerging pain management therapies, regulatory changes, telehealth utilization, global wellness trends, biosimilar competition, patient preferences, precision medicine approaches. Major trends in the forecast period include over-the-counter (OTC) market dominance, rising preference for cox-2 inhibitors, generics and market competition, integration of digital health technologies, integration of digital health technologies.

The increasing prevalence of chronic pain is projected to drive the growth of the non-steroidal anti-inflammatory drugs (NSAIDs) market. Chronic pain is defined as discomfort that lasts for more than six months, and NSAIDs are commonly used to treat injuries and manage chronic pain. For example, a survey published in July 2022 by the U.S. Pain Foundation, a nonprofit organization based in the U.S., found that 96% of the 2,378 participants reported experiencing increased chronic pain, defined as pain persisting for three months or longer. This included 3% of caregivers and 1% of healthcare professionals surveyed from March to April 2022. Thus, the rising incidence of chronic pain is a key factor driving the growth of the NSAIDs market.

Increasing prevalence of musculoskeletal disorders (MSDs) is set to fuel the growth of the NSAIDs market. MSDs encompass a range of conditions impacting the musculoskeletal system and often requiring pain and inflammation management, for which NSAIDs serve as key therapeutic agents. Factors like an aging demographic, enhanced disease awareness, and greater orthopedic interventions contribute to this surge. A profile by GOV.UK in December 2022 highlighted the upsurge in the prevalence of MSDs among UK individuals aged 16 and above, pointing to a rise from 2021. This escalation underscores the market's trajectory, propelled by the increasing burden of musculoskeletal conditions and the role of NSAIDs in their management.

Product innovation is a significant trend in the non-steroidal anti-inflammatory drugs (NSAIDs) market. Leading companies in this sector are focusing on developing new technological solutions. For example, in February 2024, Hyloris Pharmaceuticals, a Belgium-based firm that specializes in reformulating existing drugs to meet unmet medical needs, launched Maxigesic IV. This intravenous formulation combines paracetamol (acetaminophen) and ibuprofen for the effective management of moderate to severe pain, particularly in postoperative settings. This combination offers enhanced analgesic effects compared to using either drug alone, resulting in more effective pain relief. The intravenous delivery of Maxigesic IV facilitates a rapid onset of action, making it well-suited for acute pain management in clinical environments.

Industry leaders in the NSAIDs market are pursuing new combination therapies to gain competitive advantages. Combination therapies entail the simultaneous use of multiple therapeutic agents or treatments to amplify efficacy or address diverse facets of a condition. For instance, in August 2022, Haleon PLC, a UK-based consumer healthcare company, introduced Advil PLUS Acetaminophen in Canada. This tablet combines ibuprofen and acetaminophen, providing a dual mechanism for pain relief across various pain types. The fusion of these two agents in a single tablet offers an accessible, non-prescription option for pain management, ensuring prolonged relief for up to eight hours. Advil PLUS Acetaminophen stands as an over-the-counter solution available in multiple retail outlets in Canada, showcasing the market's emphasis on effective combination therapies.

In March 2022, Pfizer, a prominent U.S.-based pharmaceutical and biotechnology company, acquired Arena Pharmaceuticals for an undisclosed sum. This strategic move enables Pfizer to access Arena Pharmaceuticals' diverse pipeline of developmental-stage therapeutic candidates primarily focused on dermatology, gastroenterology, and cardiology. Notably, this includes etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator currently undergoing development for various immuno-inflammatory diseases like Crohn's disease, ulcerative colitis, atopic dermatitis, eosinophilic esophagitis, and alopecia. Arena Pharmaceuticals, a U.S.-based company specializing in non-steroidal anti-inflammatory drugs, brings this portfolio of innovative treatments to Pfizer through this acquisition.

Major companies operating in the non-steroidal anti-inflammatory drugs market are Pfizer Inc., Bayer AG, Johnson & Johnson, Sun Pharmaceutical Industries Ltd., Assertio Therapeutics Inc., Iroko Pharmaceuticals Inc., Reckitt Benckiser Group PLC, Perrigo Company PLC, Hikma Pharmaceuticals Public Limited Company, Glenmark Pharmaceuticals Limited, Septodont, Aspen Pharmacare Holdings Limited, Sagent Pharmaceuticals Inc., Advanced Pharma Inc., Akorn Operating Company LLC, Alembic Pharmaceuticals Limited, Torrent Pharmaceuticals Limited, Lupin Limited, Cipla Limited, Zydus Cadila Healthcare Limited, Aurobindo Pharma Limited, Sanofi S.A., GlaxoSmithKline PLC, Horizon Therapeutics PLC, Zyla Life sciences, Novartis AG, Roche Holding AG, AbbVie Inc., Bristol-Myers Squibb Company

North America was the largest region in the non-steroidal anti-inflammatory drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the non-steroidal anti-inflammatory drugs market during the forecast period. The regions covered in the non-steroidal anti-inflammatory drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-steroidal anti-inflammatory drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-steroidal anti-inflammatory drugs market consists of sales of high-dose aspirin, indomethacin, mefenamic acid, celecoxib, and other types. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Steroidal Anti-inflammatory Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-steroidal anti-inflammatory drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-steroidal anti-inflammatory drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-steroidal anti-inflammatory drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Route Of Administration: Oral; Topical; Other Route Of Administration
• 2) By Disease Indication: Arthritis; Migraine; Ophthalmic Diseases; Other Disease Indications
• 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• Subsegments:
• 1) By Oral: Tablets; Capsules; Liquids Or Solutions
• 2) By Topical: Gels; Creams; Patches
• 3) By Other Route Of Administration: Injectable (Intravenous And Intramuscular); Suppositories
• Companies Mentioned: Pfizer Inc.; Bayer AG; Johnson & Johnson; Sun Pharmaceutical Industries Ltd.; Assertio Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Non-Steroidal Anti-inflammatory Drugs Market Characteristics

3. Non-Steroidal Anti-inflammatory Drugs Market Trends And Strategies

4. Non-Steroidal Anti-inflammatory Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Non-Steroidal Anti-inflammatory Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Non-Steroidal Anti-inflammatory Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Non-Steroidal Anti-inflammatory Drugs Market Growth Rate Analysis
• 5.4. Global Non-Steroidal Anti-inflammatory Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Non-Steroidal Anti-inflammatory Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Non-Steroidal Anti-inflammatory Drugs Total Addressable Market (TAM)

6. Non-Steroidal Anti-inflammatory Drugs Market Segmentation

• 6.1. Global Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Topical
• Other Route of Administration
• 6.2. Global Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Arthritis
• Migraine
• Ophthalmic Diseases
• Other Disease Indications
• 6.3. Global Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.4. Global Non-Steroidal Anti-inflammatory Drugs Market, Sub-Segmentation Of Oral, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablets
• Capsules
• Liquids Or Solutions
• 6.5. Global Non-Steroidal Anti-inflammatory Drugs Market, Sub-Segmentation Of Topical, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gels
• Creams
• Patches
• 6.6. Global Non-Steroidal Anti-inflammatory Drugs Market, Sub-Segmentation Of Other Route Of Administration, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectable (Intravenous And Intramuscular)
• Suppositories

7. Non-Steroidal Anti-inflammatory Drugs Market Regional And Country Analysis

• 7.1. Global Non-Steroidal Anti-inflammatory Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Non-Steroidal Anti-inflammatory Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Non-Steroidal Anti-inflammatory Drugs Market

• 8.1. Asia-Pacific Non-Steroidal Anti-inflammatory Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Non-Steroidal Anti-inflammatory Drugs Market

• 9.1. China Non-Steroidal Anti-inflammatory Drugs Market Overview
• 9.2. China Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Non-Steroidal Anti-inflammatory Drugs Market

• 10.1. India Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Non-Steroidal Anti-inflammatory Drugs Market

• 11.1. Japan Non-Steroidal Anti-inflammatory Drugs Market Overview
• 11.2. Japan Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Non-Steroidal Anti-inflammatory Drugs Market

• 12.1. Australia Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Non-Steroidal Anti-inflammatory Drugs Market

• 13.1. Indonesia Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Non-Steroidal Anti-inflammatory Drugs Market

• 14.1. South Korea Non-Steroidal Anti-inflammatory Drugs Market Overview
• 14.2. South Korea Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Non-Steroidal Anti-inflammatory Drugs Market

• 15.1. Western Europe Non-Steroidal Anti-inflammatory Drugs Market Overview
• 15.2. Western Europe Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Non-Steroidal Anti-inflammatory Drugs Market

• 16.1. UK Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Non-Steroidal Anti-inflammatory Drugs Market

• 17.1. Germany Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Non-Steroidal Anti-inflammatory Drugs Market

• 18.1. France Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Non-Steroidal Anti-inflammatory Drugs Market

• 19.1. Italy Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Non-Steroidal Anti-inflammatory Drugs Market

• 20.1. Spain Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Non-Steroidal Anti-inflammatory Drugs Market

• 21.1. Eastern Europe Non-Steroidal Anti-inflammatory Drugs Market Overview
• 21.2. Eastern Europe Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Non-Steroidal Anti-inflammatory Drugs Market

• 22.1. Russia Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Non-Steroidal Anti-inflammatory Drugs Market

• 23.1. North America Non-Steroidal Anti-inflammatory Drugs Market Overview
• 23.2. North America Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Non-Steroidal Anti-inflammatory Drugs Market

• 24.1. USA Non-Steroidal Anti-inflammatory Drugs Market Overview
• 24.2. USA Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Non-Steroidal Anti-inflammatory Drugs Market

• 25.1. Canada Non-Steroidal Anti-inflammatory Drugs Market Overview
• 25.2. Canada Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Non-Steroidal Anti-inflammatory Drugs Market

• 26.1. South America Non-Steroidal Anti-inflammatory Drugs Market Overview
• 26.2. South America Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Non-Steroidal Anti-inflammatory Drugs Market

• 27.1. Brazil Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Non-Steroidal Anti-inflammatory Drugs Market

• 28.1. Middle East Non-Steroidal Anti-inflammatory Drugs Market Overview
• 28.2. Middle East Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Non-Steroidal Anti-inflammatory Drugs Market

• 29.1. Africa Non-Steroidal Anti-inflammatory Drugs Market Overview
• 29.2. Africa Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Non-Steroidal Anti-inflammatory Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Non-Steroidal Anti-inflammatory Drugs Market Competitive Landscape And Company Profiles

• 30.1. Non-Steroidal Anti-inflammatory Drugs Market Competitive Landscape
• 30.2. Non-Steroidal Anti-inflammatory Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sun Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Assertio Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Non-Steroidal Anti-inflammatory Drugs Market Other Major And Innovative Companies

• 31.1. Iroko Pharmaceuticals Inc.
• 31.2. Reckitt Benckiser Group PLC
• 31.3. Perrigo Company PLC
• 31.4. Hikma Pharmaceuticals Public Limited Company
• 31.5. Glenmark Pharmaceuticals Limited
• 31.6. Septodont
• 31.7. Aspen Pharmacare Holdings Limited
• 31.8. Sagent Pharmaceuticals Inc.
• 31.9. Advanced Pharma Inc.
• 31.10. Akorn Operating Company LLC
• 31.11. Alembic Pharmaceuticals Limited
• 31.12. Torrent Pharmaceuticals Limited
• 31.13. Lupin Limited
• 31.14. Cipla Limited
• 31.15. Zydus Cadila Healthcare Limited

32. Global Non-Steroidal Anti-inflammatory Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non-Steroidal Anti-inflammatory Drugs Market

34. Recent Developments In The Non-Steroidal Anti-inflammatory Drugs Market

35. Non-Steroidal Anti-inflammatory Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Non-Steroidal Anti-inflammatory Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Non-Steroidal Anti-inflammatory Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Non-Steroidal Anti-inflammatory Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer